Indication

Schizophrenia

Clinical and regulatory intelligence for Schizophrenia with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 0
Catalysts: 2
Assets: 2

Relevant assets

Emraclidine →

KarXT →

Relevant companies

AbbVie →

Karuna Therapeutics →

Recent signals

No signals indexed for this entity yet.

Upcoming catalysts(2)

Phase II Readout

AbbVie — Emraclidine

Second-wave muscarinic data will clarify class viability post-KarXT launch.

September 18, 2026 · Phase II

Commercial Launch

Karuna Therapeutics — KarXT

First-in-class muscarinic agonist launch tests payer appetite for novel MOA in psychiatry.

June 18, 2026 · Commercial

Therapeutic areas

Neuropsychiatry →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.